New Scientist reports on recent forays into the field of psychedelic research. Once a booming area, Timothy Leary’s wildness soured the establishment’s enthusiasm, and money dried up. Until recently, that is, as scientists have been finding it easier to raise funding for studies centred on the beneficial effects of the compounds.

Halpern is now an associate director of substance abuse research at Harvard University’s McLean Hospital and is at the forefront of a revival of research into psychedelic medicine. He recently received approval from the US Food and Drug Administration (FDA) to give late-stage cancer patients the psychedelic drug MDMA, also known as ecstasy. He is also laying the groundwork for testing LSD as a treatment for dreaded super-migraines known as cluster headaches.

Related Leave a Comment